Global Postmenopausal Osteoporosis Drugs Market 2016-2020
SKU ID :TNV-10278943 | Published Date: 11-May-2016 | No. of pages: 60Description
About the Postmenopausal Osteoporosis Drugs Market
Bones have the ability to grow and heal naturally, but changes in diet, exercise levels, and body chemistry lead to changes in the bone mineral density. This results in osteoporosis, which is characterized by low bone density and structural deterioration of bone tissues, leading to fragile bones. Rapid bone resorption or slow bone replacement can result in the development of the disease. Gender, age, body size (low body weight), ethnicity, and family history also play a role in developing osteoporosis. Other risk factors include medication, calcium and vitamin intake, alcohol intake, and smoking.
Women are at a greater risk of developing osteoporosis than men as estrogens play an important role in maintaining bone strength. Small amounts of bone are lost as part of normal aging process, but on reaching menopause, estrogen levels decline drastically, leading to a greater risk of developing osteoporosis.
Technavio’s analysts forecast the Global Postmenopausal Osteoporosis Drugs Market to grow at a CAGR of 4.02% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the Global Postmenopausal Osteoporosis Drugs Market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent postmenopausal osteoporosis.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Postmenopausal Osteoporosis Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Eli Lilly
• Amgen
• Merck
• Novartis
Other prominent vendors
• Allergan
• Amgen Astellas Biopharm
• Deltanoid Pharmaceuticals
• Noven
• Novo Nordisk
• Osteologix
• Pfizer
• PhytoHealth
• Radius Health
• Tarsa Therapeutics
• UCB
• Uni-Bio Science Group
• Upsher-Smith Laboratories
• Watson Pharmaceuticals
• Zosano Pharma
Market driver
• Growing prevalence of postmenopausal osteoporosis
• For a full, detailed list, view our report
Market challenge
• Low diagnosis rate
• For a full, detailed list, view our report
Market trend
• Emergence of novel agents
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Bones have the ability to grow and heal naturally, but changes in diet, exercise levels, and body chemistry lead to changes in the bone mineral density. This results in osteoporosis, which is characterized by low bone density and structural deterioration of bone tissues, leading to fragile bones. Rapid bone resorption or slow bone replacement can result in the development of the disease. Gender, age, body size (low body weight), ethnicity, and family history also play a role in developing osteoporosis. Other risk factors include medication, calcium and vitamin intake, alcohol intake, and smoking.
Women are at a greater risk of developing osteoporosis than men as estrogens play an important role in maintaining bone strength. Small amounts of bone are lost as part of normal aging process, but on reaching menopause, estrogen levels decline drastically, leading to a greater risk of developing osteoporosis.
Technavio’s analysts forecast the Global Postmenopausal Osteoporosis Drugs Market to grow at a CAGR of 4.02% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the Global Postmenopausal Osteoporosis Drugs Market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent postmenopausal osteoporosis.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Postmenopausal Osteoporosis Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Eli Lilly
• Amgen
• Merck
• Novartis
Other prominent vendors
• Allergan
• Amgen Astellas Biopharm
• Deltanoid Pharmaceuticals
• Noven
• Novo Nordisk
• Osteologix
• Pfizer
• PhytoHealth
• Radius Health
• Tarsa Therapeutics
• UCB
• Uni-Bio Science Group
• Upsher-Smith Laboratories
• Watson Pharmaceuticals
• Zosano Pharma
Market driver
• Growing prevalence of postmenopausal osteoporosis
• For a full, detailed list, view our report
Market challenge
• Low diagnosis rate
• For a full, detailed list, view our report
Market trend
• Emergence of novel agents
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
TOC
Tables & Figures
Companies
- PRICE
-
$2500$4000Buy Now